罗米非定 | 65896-16-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 罗米非定
• 英文名称: romifidine
• 英文别名: N-(2-bromo-6-fluorophenyl)-4,5-dihydro-1H-imidazol-2-amine
• CAS: 65896-16-4
• 化学式: C₉H₉BrFN₃
• mdl: MFCD00868606
• 分子量: 258.093
• InChiKey: KDPNLRQZHDJRFU-UHFFFAOYSA-N

物化性质

• 熔点：
  110 °C
• 沸点：
  303.2±52.0 °C(Predicted)
• 密度：
  1.72±0.1 g/cm3(Predicted)
• 溶解度：
  DMSO：250 mg/mL（968.65 mM；需要超声波）

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  36.4
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2933290090

反应信息

• 作为反应物：
  描述：

  罗米非定 、 环丙基甲基氯 在 sodium carbonate 作用下， 以 甲醇 为溶剂， 反应 23.0h， 以30.8%的产率得到(2-Bromo-6-fluoro-phenyl)-cyclopropylmethyl-(4,5-dihydro-1H-imidazol-2-yl)-amine
  参考文献：
  名称：

  Chemistry, pharmacology, and structure-activity relationships with a new type of imidazolines exerting a specific bradycardic action at a cardiac site

  摘要：

  The reaction of alkyl halides with 2-(arylimino)imidazolidines (I) leads to imidazoline derivatives II, in which the side chain is situated at the bridge nitrogen atom between the phenyl group and the imidazoline ring. The new imidazolines (II) exert a specific bradycardic action at a cardiac site. Syntheses and pharmacology are shown and structure-activity relationships discussed. The results reveal that the imidazoline derivatives (II) represent a class of compounds with a novel type of cardiac action.

  DOI：

  10.1021/jm00185a013

文献信息

• [EN] DEUTERATED MORPHINE DERIVATIVES<br/>[FR] DÉRIVÉS DE MORPHINE DEUTÉRÉS
  申请人：SZEGEDI TUDOMÁNYEGYETEM

  公开号：WO2014170704A1

  公开（公告）日：2014-10-23

  The invention relates to new morphine derivatives deuterated at the 7,8-position of the morphine ring, furthermore to a process for the preparation thereof, and to pharmaceutical compositions comprising them. The new deuterated morphine derivatives show high and selective μ-opioid receptor binding activity leading to the benefit of higher analgesic activity at lower dosages inducing thereby reduced adverse effects compared to the hydrogenated derivatives. The compounds of the invention are useful for example in the treatment of pain or can be used as antitussive agents with a reduced risk of the possibility of drug abuse.

  这项发明涉及新的吗啡衍生物，其在吗啡环的7,8-位置被氘代取，此外还涉及其制备方法以及包含它们的药物组合物。这些新的氘代吗啡衍生物显示出高度和选择性的μ-阿片受体结合活性，从而在较低剂量下产生更高的镇痛活性，因此与氢化衍生物相比，减少了不良反应。该发明的化合物可用于例如治疗疼痛，或可用作镇咳剂，具有较低的药物滥用可能性。
• [EN] ADRENERGIC RECEPTOR MODULATING COMPOUNDS AND METHODS OF USING THE SAME<br/>[FR] COMPOSÉS DE MODULATION DES RÉCEPTEURS ADRÉNERGIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2017197324A1

  公开（公告）日：2017-11-16

  Adrenergic receptor modulating compounds and methods of using the same are provided. Also provided are methods of treating a subject for a disease or condition associated with an adrenergic receptor including administering a therapeutically effective amount of the subject compound. Aspects of the disclosure include a method of modulating an inflammatory pathway in a cell, such as the production of TNF-alpha in the cell. The method can include contacting a cell with a β1-selective adrenergic receptor modulating compound to selectively activate a cAMP pathway over a beta-arrestin pathway in the cell. Pharmaceutical compositions and kits which include the subject compounds are provided.

  提供了调节肾上腺素受体的化合物及使用方法。还提供了治疗与肾上腺素受体相关疾病或症状的方法，包括向受试者施用治疗有效量的该化合物。本公开的方面包括一种调节细胞中炎症通路的方法，例如在细胞中产生TNF-alpha。该方法可以包括将细胞与β1选择性肾上腺素受体调节化合物接触，以在细胞中选择性激活cAMP通路而不是β-arrestin通路。还提供了包含该化合物的药物组合物和试剂盒。
• Method For Improved Bioactivation Of Pharmaceuticals
  申请人：Clement Bernd

  公开号：US20120077876A1

  公开（公告）日：2012-03-29

  This invention relates to a prodrug comprising a partial structure having the general formula (I) or (II), where R 1 and R 2 are hydrogen, alkyl, or aryl radicals.

  这项发明涉及一种前药，其包含具有一般式(I)或(II)的部分结构，其中R1和R2为氢、烷基或芳基基团。
• [EN] METHODS AND COMPOSITIONS FOR HYPOTENSIVE RESUSCITATION<br/>[FR] PROCÉDÉ ET COMPOSITIONS POUR LA RÉANIMATION HYPOTENSIVE
  申请人：PHARMAZZ INC

  公开号：WO2014035446A1

  公开（公告）日：2014-03-06

  Methods of treating diseases and conditions wherein an improvement in cardiac output, organ perfusion, or tissue oxygenation are disclosed. The methods include treatments of diseases and conditions, such as hypovolemic shock, with an a2 adrenergic agent, like centhaquin and centhaquin citrate. The method utilizes an a2 adrenergic agent administered at low doses with a low volume of resuscitation fluid. Purified centhaquin and centhaquin citrate also are disclosed.

  本发明揭示了一种治疗疾病和病况的方法，其中改善心输出量、器官灌注或组织氧合是必要的。该方法包括使用a2肾上腺素受体激动剂（如centhaquin和centhaquin citrate）治疗低血容量休克等疾病和病况。该方法利用低剂量的a2肾上腺素受体激动剂和低灌注液体量进行治疗。本发明还揭示了纯化的centhaquin和centhaquin citrate。
• Compounds and methods for treating urinary incontinence
  申请人：Boehringer Ingelheim Pharma Gmbh & Co. KG

  公开号：US20040198796A1

  公开（公告）日：2004-10-07

  Compounds of the formula (II) 1 wherein R 1 , R 2 , R 3 , R 4 , and R 5 are as set forth herein, pharmaceutical compositions containing them, and their use in treating urinary incontinence.

  化学式为（II）的化合物，其中R1，R2，R3，R4和R5如此规定，包含它们的制药组合物以及它们在治疗尿失禁中的使用。